Eisai Co.’s breakthrough Alzheimer’s drug Leqembi was cleared for use in the European Union, after the medicine was approved ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat mild cognitive impairment in the early stages of Alzheimer's disease.

The antibody lecanemab is the first authorized therapy in Europe that targets the underlying process of Alzheimer's, rather than only treating symptoms.

If someone with dementia isn’t hungry, you can meal prep for them and encourage them to eat small bites. Find out how to get ...

FTD is the leading cause of dementia for those under age 60, and it is an indescribably cruel disease, decimating lives and often masquerading as something else completely. It can mimic psychiatric ...

A new study found that emergency room visits and hospitalizations tied to cannabis use among older adults has skyrocketed since the early 2000s.

A virus that has infected about two thirds of Britons, and millions more worldwide, could increase the risk of developing the ...

Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s ...

Santa Lucia Foundation IRCCS-led research is reporting that repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus may slow the progression of cognitive decline, impairments in ...

Dementia is the UK's biggest killer, claiming more lives than heart attacks and strokes combined. Despite exhaustive research ...

A research team has identified a previously unknown enzyme, SIRT2, that plays a key role in memory loss associated with Alzheimer's disease (AD). The study provides critical insights into how ...

Scroll down to learn more about the challenges many caregivers face—and download Elevmi to learn more about how it can ...